Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery

Investigator team will compare patients who continue SGLT-2 inhibitors preoperatively with those who discontinue SGLT-2 inhibitors 3 days before surgery. Patients scheduled for elective cardiac surgery with cardiopulmonary bypass will be seen in an anesthesia consultation at least 4 days before surgery. During the consultation, the study will be proposed to the patient. After receiving written information and signing the informed consent form, baseline data, will be collected, and the patient will be randomized into one of the two study groups. The patient and the anesthesia and cardiac surgery teams will not be blinded. Indeed, Investigator team aim to conduct a pragmatic study that closely reflects clinical reality. Postoperatively, patients will be managed according to each service's usual practices. Investigator team's goal is to reflect real-world conditions. Following surgery, SGLT-2 inhibitors will be administrated once hemodynamics are stable. Five visits are scheduled in the protocol: 4 at 7 days before surgery, the day before surgery, at 7 days, upon hospital discharge, and 30 days after the intervention to assess the occurrence of the various outcome criteria.

Inclusion criteria

• Adult patients scheduled to undergo cardiac surgery with cardiopulmonary bypass
• patients treated with SGLT-2 inhibitors, including combined treatment with metformin, for at least 4 weeks
• heart failure patients with a left ventricular ejection fraction strictly below 50%
• patients enrolled in a social security scheme or equivalent
• patients who have signed the informed consent form

Exclusion criteria

• Treatment with SGLT-2 inhibitors initiated less than 4 weeks ago and other than empagliflozine or dapagliflozine
• patients with a contraindication to SGLT-2 inhibitors: hypersensitivity, type 1 diabetes mellitus, and renal impairment with an estimated glomerular filtration rate below 25 mL/min/1.73 m²
• acute conditions likely to call into question the continuation of SGLT2 inhibitor therapy (alone or in combination) at the time of inclusion, including in particular: shock state or acute tissue hypoxia (episode of hyperlactatemia > 3 mmol/L within 7 days prior to inclusion); acute kidney injury within the previous 7 days (KDIGO stage ≥2); severe hepatocellular failure (factor V level < 50%); acute alcohol intoxication within the previous 7 days or active alcohol use disorder without withdrawal
• surgery scheduled within less than 3 days
• surgery for active endocarditis within the last 3 months
• patients on preoperative mechanical circulatory support
• heart transplant surgery or implantation of an LVAD (left ventricular assist device)
• chronic kidney disease patients with a glomerular filtration rate below 25 mL/min/1.73m²
• heart failure patients with a preserved ejection fraction, equal to or greater than 50
• pregnant or breastfeeding women
• minors or adults under legal protection (guardianship or conservatorship)
• patients participating in another interventional study patients who do not understand or speak French.